{"id":"experimental-drug-olanzapine","safety":{"commonSideEffects":[{"rate":"~10-15%","effect":"Weight gain"},{"rate":"~20-30%","effect":"Sedation"},{"rate":"~5-10%","effect":"Metabolic syndrome/hyperglycemia"},{"rate":"~5-10%","effect":"Hyperlipidemia"},{"rate":"~5%","effect":"Akathisia"},{"rate":"~5%","effect":"Orthostatic hypotension"},{"rate":"~10%","effect":"Prolactin elevation"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing psychotic symptoms, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. It also has activity at multiple other receptors including muscarinic, histamine H1, and alpha-adrenergic receptors, contributing to its broader pharmacological profile.","oneSentence":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:55.442Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Treatment-resistant depression (adjunctive use)"}]},"trialDetails":[{"nctId":"NCT07208305","phase":"PHASE3","title":"Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting","status":"RECRUITING","sponsor":"Affiliated Hospital of Qinghai University","startDate":"2026-02-03","conditions":"Nausea, Vomiting","enrollment":222},{"nctId":"NCT04216329","phase":"PHASE1","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-07","conditions":"Gliosarcoma, Newly Diagnosed, Glioblastoma","enrollment":11},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT06314906","phase":"PHASE3","title":"Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Feixue Song","startDate":"2024-03-07","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT04535141","phase":"PHASE3","title":"Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2020-08-18","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":91},{"nctId":"NCT03079219","phase":"PHASE3","title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients","status":"COMPLETED","sponsor":"CCTU","startDate":"2017-03-23","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT01567124","phase":"PHASE4","title":"Alleviating the Metabolic Side Effects of Antipsychotic Medications","status":"WITHDRAWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-05","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT02593734","phase":"PHASE4","title":"Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana","status":"COMPLETED","sponsor":"University of Ghana Medical School","startDate":"2013-07","conditions":"Schizophrenia, Mood Disorders,, Anxiety Disorder","enrollment":139},{"nctId":"NCT02290470","phase":"PHASE2","title":"Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2014-04","conditions":"Nausea, Vomiting","enrollment":81},{"nctId":"NCT00654576","phase":"PHASE4","title":"Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Central South University","startDate":"2005-02","conditions":"Schizophrenia","enrollment":1400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental drug: Olanzapine","genericName":"Experimental drug: Olanzapine","companyName":"CCTU","companyId":"cctu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Treatment-resistant depression (adjunctive use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}